Symbiotec Pharmalab IPO
Open Date
24 Aug 2026
Close Date
27 Aug 2026
Open Date
24 Aug 2026
Close Date
27 Aug 2026
Min Investment
Lot Size
Issue Size
Price Range
Subscribed

Founded In
2002
Director
Rohit Mantri
Financials of Symbiotec Pharmalab IPO
| Key Performance Indicators | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Operating Revenue | 716.25 | 751.55 | 869.15 |
| Other Income | 7.09 | 4.42 | 3.11 |
Total Income | 723.33 | 755.98 | 872.26 |
Total Expenses | 590.99 | 608.85 | 709.90 |
| Profit Before Tax | 130.98 | 146.97 | 153.36 |
Total Profit | 100.06 | 96.79 | 109.90 |
All figures are in crores (₹)

Utilisation of Proceeds
All figures are in crores (₹)
| Purpose | Amount |
|---|---|
| The company proposes to utilize the net proceeds towards prepayment and/or repayment, in full or in part, of certain outstanding borrowings to reduce overall indebtedness, debt servicing costs, and maintain favorable debt-equity ratio. | 113 |
| The company proposes to utilize the balance net proceeds for general corporate purposes including meeting ongoing contingencies, business requirements, funding growth opportunities, and strategic initiatives as approved by the Board. | - |

- Global leadership in corticosteroid and steroidal-hormone APIs: The company holds a global leadership position with 38.2% market share in corticosteroid and 23.8% in steroidal-hormone APIs in Fiscal 2026, being the only company globally with presence across top 10 APIs in this category.
- Long-standing relationships with domestic and global customer base: The company serves over 200 customers across 40+ countries with average relationship tenure of more than 10 years with top customers, demonstrating strong customer stickiness and retention capabilities.
- Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record: The company operates with 584.67 MT chemical synthesis capacity, 700 KL fermentation capacity, and 20 million vials complex injectables capacity, having completed 108+ inspections without critical observations from global regulators.
- Continuous investment in R&D, with leading technological capabilities among Indian peers: The company invested 3.42% of revenue in R&D in Fiscal 2026 with 156 scientists across three platforms, enabling manufacturing of APIs with up to 400 synthesis steps validated under cGMP.
- Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings: The company successfully expanded into classical fermentation APIs, CDMO services with take-or-pay contracts, and complex injectables commanding 20-50% price premium over conventional injectables.
- Robust financials with strong gross margins, high capital efficiency and cash conversion: The company achieved revenue CAGR of 10.16% (Fiscal 2024-2026), gross margins of 63.70% in Fiscal 2026, and maintained CARE A+ credit rating across three consecutive fiscals.
- Seasoned leadership team supported by strong pool of experienced management and marquee investors: The company is led by experienced management with 30+ years pharmaceutical experience, backed by marquee investors including Rosewood Investments, Motilal Oswal Alternates, and historically Actis and Franklin Templeton.

